This Biotech Has a June 30 FDA Catalyst. A Fund Simply Minimize Its Stake by $7 Million

HighVista Methods reported a sale of 238,243 shares of Viridian Therapeutics (NASDAQ:VRDN) in its Could 15, 2026, SEC submitting, an estimated $7.08 million commerce primarily based on quarterly common pricing.

What occurred

Based on a SEC submitting dated Could 15, 2026, HighVista Methods diminished its stake in Viridian Therapeutics (NASDAQ:VRDN) by 238,243 shares in the course of the first quarter. The estimated worth of shares offered was about $7.08 million, primarily based on the interval’s common closing worth. After accounting for inventory worth actions, the quarter-end worth of the place declined by $8.97 million.

What else to know

• Prime holdings after this submitting:

  • NYSEMKT:DBC: $30.61 million (8.5% of AUM)

  • NASDAQ:ABVX: $12.61 million (3.5% of AUM)

  • NASDAQ:PRAX: $8.48 million (2.3% of AUM)

  • NASDAQ:COGT: $7.58 million (2.1% of AUM)

  • NASDAQ:SYRE: $7.38 million (2.0% of AUM)

• As of Could 14, 2026, shares of Viridian Therapeutics have been priced at $17.43, up about 35% over the previous 12 months and nicely outperforming the S&P 500’s roughly 25% acquire.

Firm overview

Firm snapshot

• Viridian Therapeutics develops monoclonal antibody therapies, together with VRDN-001, VRDN-002, and VRDN-003, primarily focusing on thyroid eye illness (TED).

• The agency operates a biotechnology enterprise mannequin centered on analysis, medical growth, and out-licensing or commercialization of proprietary therapeutic candidates.

• It targets sufferers with severe illnesses, with a main give attention to the healthcare and biotechnology sectors.

Viridian Therapeutics is a clinical-stage biotechnology firm specializing within the growth of antibody-based therapies for severe illnesses, with an emphasis on thyroid eye illness. The corporate leverages superior monoclonal antibody expertise to handle unmet medical wants in its goal markets. Its strategic give attention to modern biologics positions it to compete within the evolving panorama of specialty therapeutics.

What this transaction means for traders

Viridian has climbed roughly 35% over the previous 12 months, and with a June 30 FDA choice looming for lead remedy veligrotug, some traders could also be locking in features. The corporate additionally confronted some strain proper on the finish of final quarter, with shares falling over 30% after the agency reported Part 3 TED information that was constructive, however fell in need of expectations.

Nonetheless, the broader enterprise momentum continues to look strong. Earlier this month, Viridian mentioned it’s “launch-ready” forward of veligrotug’s PDUFA date and highlighted constructive Part 3 information for subcutaneous candidate elegrobart in each lively and power thyroid eye illness. Administration believes elegrobart may change into the primary subcutaneous autoinjector therapy for TED, probably giving the corporate a differentiated industrial angle in a market presently dominated by infusions.

For long-term traders, the story now more and more hinges on execution. A profitable FDA approval and launch may materially reshape Viridian’s profile from a development-stage biotech right into a industrial uncommon illness participant.

Do you have to purchase inventory in Viridian Therapeutics proper now?

Before you purchase inventory in Viridian Therapeutics, take into account this:

The Motley Idiot Inventory Advisor analyst crew simply recognized what they consider are the 10 greatest shares for traders to purchase now… and Viridian Therapeutics wasn’t certainly one of them. The ten shares that made the minimize may produce monster returns within the coming years.

Think about when Netflix made this record on December 17, 2004… for those who invested $1,000 on the time of our advice, you’d have $469,293!* Or when Nvidia made this record on April 15, 2005… for those who invested $1,000 on the time of our advice, you’d have $1,381,332!*

Now, it’s price noting Inventory Advisor’s complete common return is 993% — a market-crushing outperformance in comparison with 207% for the S&P 500. Do not miss the most recent prime 10 record, out there with Inventory Advisor, and be a part of an investing neighborhood constructed by particular person traders for particular person traders.

See the ten shares »

*Inventory Advisor returns as of Could 17, 2026.

Jonathan Ponciano has no place in any of the shares talked about. The Motley Idiot has no place in any of the shares talked about. The Motley Idiot has a disclosure coverage.

This Biotech Has a June 30 FDA Catalyst. A Fund Simply Minimize Its Stake by $7 Million was initially revealed by The Motley Idiot